Back

Aimed Bio expands from ADCs to AOCs with 3 trillion won in deals

Verifying
  • Aimed Bio is expanding its research from ADCs into AOCs and central nervous system diseases.
  • Aimed Bio signed licensing and joint development agreements worth 3 trillion won ($2.2 billion).
  • Biohaven confirmed objective responses in a Phase 1 trial of licensed ADC AMB302.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.